Incidence

The Labs on 121 Becomes the First Development to Install View Smart Windows in Harlem’s Growing Life Sciences Cluster

Retrieved on: 
Wednesday, January 11, 2023
Wall Street, Eye, Tenant, GLARE, Sleep, Durst Organization, Health, Region, Headache, Partnership, Growth, Intelligence, Research, View, Inc., TIAA, Science, Dust, Labs, Organic, Incidence, Life, Tumbler (glass), Management

NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Nightingale Properties and Real Estate Equities Corporation announced their new 10-story, 160,000-square-foot office development in uptown Manhattan’s Harlem market, will feature Smart Windows from View, Inc. (Nasdaq: VIEW) (“View”), the leader in smart building platforms and smart glass. The Labs on 121, located at 2226 Third Avenue, marks the second partnership between View and Nightingale, following the 111 Wall Street office redevelopment with InterVest Capital Partners (formerly Wafra Capital Partners). It also represents View’s third project in Manhattan’s Third Avenue office corridor, following the recently completed 825 Third Avenue with the Durst Organization, and 730 Third Avenue with TIAA and Nuveen Real Estate, showcasing View’s accelerating growth in New York City.

Key Points: 
  • New York City has stated its commitment to become a market frontrunner for life sciences through capital support and government incentives.
  • The Labs on 121 represents the latest development in Harlem’s life sciences cluster and the first building in the area to install View technology.
  • Smart glass also offers significant health advantages to employees by reducing the incidence of eyestrain and headaches by over 50 percent.
  • In a recent study, employees working next to View Smart Windows improved their sleep by 37 minutes per night and cognitive function by 42 percent.

Provectus Biopharmaceuticals Releases 2023 Stockholder Letter

Retrieved on: 
Monday, January 9, 2023
Disease, OS, RECIST, Knowledge, SOC, CR, CRS, Melanoma, Cancer, University, Dermatology, Particle-size distribution, Orphan Drug Act of 1983, H. Lee Moffitt Cancer Center & Research Institute, RCT, RBS, Cumming School of Medicine, Metastasis, Combination therapy, CB, SEER, Research, ITM, ORR, Hematology, III, Incidence, Progression-free survival, Classification, PFS, Neoplasm, Rockefeller University, AJCC, Infection, Prevalence, Lymph, Meta-analysis, Clinical trial, PV-10, Cell death, Standard of care, Safety, Vaccine, Diagnosis, PRN, Survival, Patient, Pembrolizumab, Medical device, Pharmaceutical industry, Medical imaging, Television, Veterinary medicine, Epidemiology, Medicine

This effort has been utilizing Provectus’ clinical efficacy data from approximately 180 in-transit melanoma (ITM) patients treated with single-agent PV-10, as well as safety data from more than 300 melanoma patients.

Key Points: 
  • This effort has been utilizing Provectus’ clinical efficacy data from approximately 180 in-transit melanoma (ITM) patients treated with single-agent PV-10, as well as safety data from more than 300 melanoma patients.
  • ITM diagnosis is specifically associated with an overall poor prognosis and has the potential to be seriously debilitating and life threatening.
  • Furthermore, we encourage collaboration between our various researchers to assist Provectus in building the Company’s medical science platform and associated drug pipeline.
  • Provectus’ capital raising efforts will continue in 2023.

Eledon Pharmaceuticals Provides Business and Pipeline Updates

Retrieved on: 
Monday, January 9, 2023
IND, Congress, Organ transplantation, Tacrolimus, United Kingdom, Person, Thumbay Hospital, Calcineurin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Biomarker, FDA, Collection, Kidney transplantation, Food, Patient, Diabetes, Investigational New Drug, Nephrotoxicity, Clinical trial, Transplant, Incidence, Plasma protein binding, ALS, Pharmaceutical industry, Risk management, Eledone palari, IgA nephropathy, Nephrology

Every year more than 24,000 people undergo a kidney transplant in the United States, and over 240,000 Americans are living with a functioning transplanted kidney.

Key Points: 
  • Every year more than 24,000 people undergo a kidney transplant in the United States, and over 240,000 Americans are living with a functioning transplanted kidney.
  • Eledon’s investigational drug candidate, tegoprubart, seeks to address the challenges associated with current immunosuppressive transplantation regimens, such as those that administer calcineurin inhibitors (CNIs).
  • “We are excited with the progress we made last year advancing our kidney transplantation program and remain on track to achieve important milestones in 2023,” said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon.
  • As such, we do not expect to report out data in IgAN except for data relevant to our kidney transplant program, such as safety data.

Data Centric Security Global Market Report 2022: Featuring Broadcom, IBM, NetApp, Orange Cyberdefense & More - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023
Technology, Data Management, Security, Data-centric security, Confidentiality, COVID-19, BYOD, Government, Data, NetApp, Growth, Component, Revenue, Broadcom Inc., IBM, CYOD, Incidence, USD, Security, Investment, Varonis Systems, Renewable energy, Online shopping, Vertical

The global data centric security market size is expected to reach USD 23.62 billion by 2030, according to a new study.

Key Points: 
  • The global data centric security market size is expected to reach USD 23.62 billion by 2030, according to a new study.
  • The report gives a detailed insight into current market dynamics and provides analysis on future market growth.
  • The launches of solutions and services for the security of their data are boosting the market growth over the forecast period.
  • The publisher has segmented the Data-centric Security market report based on component, vertical, deployment mode, organization size, and region:
    Data Centric Security, Component Outlook (Revenue - USD Billion, 2018 - 2030)

North America AI In Cancer Diagnostics Market Report 2022: Ability to Make Diagnoses Without Professional Radiologists Boosts Sector - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023
Technology, Health, Oncology, Artificial Intelligence, Artificial intelligence, Hospital, DOE, NCI, Cancer, Lung cancer, Pathology, Government, Female, Country, The Cancer Genome Atlas, Addario Lung Cancer Medical Institute, Marvell Software Solutions Israel, AI, Cancer Breakthroughs 2020, Neoplasm, Squamous cell carcinoma, Artificiality, Wilford Hall Ambulatory Surgical Center, Component, Mortality, Lung, Male, MRI, Primary energy, Incidence, Medical device, Medical imaging, New York University, Adenocarcinoma

The new AI-featured algorithms have overpassed the abilities of professional radiologists by allowing the forecast of patient reports utilizing MRI.

Key Points: 
  • The new AI-featured algorithms have overpassed the abilities of professional radiologists by allowing the forecast of patient reports utilizing MRI.
  • However, advanced AI methods can be employed to discover the gene mutations from tumor pathology images rather than utilizing standard genomic sequencing.
  • There were 863,830 female cases and 888,905 male cases of new invasive cancer recorded in the United States in 2019.
  • The US market dominated the North America AI In Cancer Diagnostics Market by Country in 2021; thereby, achieving a market value of $146.7 million by 2028.

Acute Migraine Treatment Market Value to Exceed US$ 7.9 Billion by 2031, Reveals Transparency Market Research

Retrieved on: 
Wednesday, January 11, 2023
Migraine, Eli Lilly and Company, AbbVie, Pacific Ocean, Disease, Hoffmann-La Roche, Merck & Co., Pfizer, Teva Pharmaceuticals, Traction, Risk, Johnson & Johnson, Patient, AstraZeneca, Novartis, OTC, CGRP, Prevalence, Allergan, Incidence, US, TMR, Pharmaceutical industry

Availability of affordable treatments for migraine and its symptoms has broadened the acute migraine treatment market outlook.

Key Points: 
  • Availability of affordable treatments for migraine and its symptoms has broadened the acute migraine treatment market outlook.
  • The acute migraine treatment market size stood at US$ 2.1 Bn in 2021.
  • Recent acute migraine treatment market trends indicate that CGRP antagonists are emerging as an effective and convenient treatment for migraine and symptoms associated with acute migraine headache.
  • Key players strive to expand their product portfolio and engage in mergers and acquisitions in order to gain acute migraine treatment market shares.

EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN EUROPE

Retrieved on: 
Tuesday, January 10, 2023
Cerebral edema, Intracerebral hemorrhage, Anticoagulant, Arthralgia, Aspirin, Stroke, MRI, Dizziness, Cerebral contusion, Seizure, Hypotension, Effectiveness, Status epilepticus, Diarrhea, Clopidogrel, Alzheimer's disease, Aneurysm, Risk, Vomiting, ARIA, Chills, AND, Disease, Nausea, Patient, Intracranial hemorrhage, Vascular malformation, Cough, Paracetamol, Hypertension, Focal neurologic signs, Headache, Observation, Incidence, Tissue plasminogen activator, Confusion, Siderosis, Fever, Medical device, Pharmaceutical industry, Medical imaging, Clothing

Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

Key Points: 
  • Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
  • There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.
  • Depending on ARIA severity, use clinical judgment in considering whether to continue dosing, temporarily discontinue treatment, or permanently discontinue LEQEMBI.
  • In Study 1, 15% of LEQEMBI-treated patients, compared to 6% of placebo-treated patients, stopped study treatment because of an adverse reaction.

The Changing Scope of Enterprise Data Protection for Post-COVID IT

Retrieved on: 
Tuesday, January 10, 2023
53rd Weapons Evaluation Group, Computer security, CISO, Children's Environmental Exposure Research Study, CIO, Information privacy, Incidence, Prevalence, Management, Risk management

BOULDER, Colo., Jan. 10, 2023 /PRNewswire-PRWeb/ -- Data protection has become a board-level priority, as the business value of data and the ransomware threat rise. Meanwhile, meeting data protection requirements becomes more challenging, as cloud and container resources enter the equation and require protection alongside physical and virtualized infrastructure. As a result, data protection teams are being tasked with doing more than ever before, new influencers are entering the equation, and new solution requirements are emerging.

Key Points: 
  • Meanwhile, meeting data protection requirements becomes more challenging, as cloud and container resources enter the equation and require protection alongside physical and virtualized infrastructure.
  • To better understand current trends in Enterprise Data Protection practices, Evaluator Group surveyed over 130 enterprise customers and today released a research study covering the key findings.
  • In order to help data protection teams scale across these larger and more complex environments, 80% of respondents in Evaluator Group study have integrated public cloud resources as part of their data protection implementation, and 60% are using some form of managed services for data protection.
  • Data Protection and its cousin, Data Security is no longer a lonely job, it has just gotten harder," said Camberley Bates, Managing Director, Evaluator Group.

FDA Provides Clearance of First-Ever Device for ACL Reconstruction in Children

Retrieved on: 
Tuesday, January 10, 2023
Hospital for Special Surgery, Eugene R. Black Sr., Meta-analysis, Child, ACL, Hope, Anterior cruciate ligament reconstruction, Arthroscopy (journal), Summative assessment, Growth, DRS, HSS, Team, Patient, Anterior cruciate ligament, Education, Regulation of tobacco by the U.S. Food and Drug Administration, Adolescence, Research, Knee, Instability, PMID, Sports medicine, Physician, FDA, Femur, Tears, Food, EPUB, Sport, Surgeon, Tibia, Systematic review, Delos D. Harriman, Medial knee injuries, Seven Second Surgery, Francesco Cordasco, Ligament, FACS, MM, Risk, Pediatrics, Price M. Cobbs, Fabricant, Hospital, Autotransplantation, Medical imaging, Dentistry, Incidence, MD, Athlete, FAAP, Green

NEW YORK, Jan. 10, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has provided clearance for use of the ACL TightRope® II implant as the first-ever device for reconstructing torn knee ligaments in children and adolescents. The technology is based on a related device commonly used in adults undergoing anterior cruciate ligament (ACL) reconstruction, but with features specifically designed to accommodate the growing skeletons of young athletes. The key advantage of the new technique is that it allows surgeons to tension the graft sequentially to ensure proper fixation and strength and to utilize minimally invasive techniques to diminish damage to the growth plates while performing a successful reconstruction.

Key Points: 
  • The technology is based on a related device commonly used in adults undergoing anterior cruciate ligament (ACL) reconstruction, but with features specifically designed to accommodate the growing skeletons of young athletes.
  • Cordasco and Green also developed pediatric- and young-adolescent-specific instrumentation guides to address an increasing population of injured high-risk young athletes.
  • Until relatively recently, however, surgeons were reluctant to operate on children whose growth plates in the legs had not fused.
  • MRI Signal Intensity of Quadriceps Tendon Autograft and Hamstring Tendon Autograft 1 Year After Anterior Cruciate Ligament Reconstruction in Adolescent Athletes.

Medical Image Management Market to be Worth $7.22 Billion by 2030 - Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Meticulous Research®

Retrieved on: 
Tuesday, January 10, 2023
Cloud, Cancer, Emergency, EMR, Google Images, Research report, BridgeHead Software, Archive, Research, Geography, Sectra AB, COVID-19, USD, INFINITT Healthcare, AICA, EHR, Hospital, Growth, Fujifilm, Radiology, Impact, Vendor Neutral Archive, GE Healthcare, Investment, Pathology, Commercial software, PACS, VNA, Conditional sentence, Patient, Incidence, Prevalence, Diagnosis, Documentation, Medical imaging, Cardiology

The increasing investments in medical imaging technologies contribute to the growth of this market.

Key Points: 
  • The increasing investments in medical imaging technologies contribute to the growth of this market.
  • For instance, in October 2021, DeepSight Technology, Inc. (U.S.) announced raising USD 25 million in Series A funding.
  • Increasing demand for collaborative and patient-centered care is an opportunity for the VNA & PACS medical image management solutions.
  • As a result, the enterprise VNA effectively becomes the unified image data repository for the electronic medical record (EMR) system.